CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)--biospace med (www.biospacemed.com) announced today that it has received 510(k) clearance from the FDA (Food and Drug Administration) to market the Company’s sterEOS 2D/3D workstation for pediatric use in spine applications. The Company’s EOS ultra-low-dose imager previously has been FDA-cleared for use in pediatrics and adults, while sterEOS has previously been FDA-cleared for adult use in spine.
